BioNexus Gene Lab Corporation (BGLC)

Market Cap	49.98M
Revenue (ttm)	10.28M
Net Income (ttm)	-442,098
Shares Out	173.72M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,762
Open	0.210
Previous Close	0.297
Day's Range	0.200 - 0.296
52-Week Range	0.160 - 1.260
Beta	0.75
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About BGLC

BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on developing and commercializing molecular diagnostic tests for the early detection of diseases and personalized health management primarily in Malaysia. Its non-invasive blood tests are used to analyze changes in ribonucleic acid for the detection of Covid-19, Dengue, human immunodeficiency virus, human papillomavirus, and the risk potentiality of cancers diseases. BioNexus Gene Lab Corporation was incorporated in 2017 and is based in Kuala Lumpur, Malaysia with an additi...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Employees: 27
• Stock Exchange: OTCMKTS
• Ticker Symbol: BGLC